Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer's disease drug candidate CT1812
Exploratory proteomics identified candidate CSF biomarkers of CT1812 in SEQUEL.Molecular correlates of functional brain connectivity (qEEG) were identified.Proteins impacted by 1 month CT1812 treatment support target engagement.Pharmacodynamic changes found in synapse, immune, vesicle, and lipoprotein biologies.SEQUEL proteomics findings replicated previous trial findings with CT1812.
Authors
- Mary E. Hamby (ORCID: https://orcid.org/0000-0002-6782-1853)
- Michael Grundman
- Nicholas T. Seyfried (ORCID: https://orcid.org/0000-0002-4507-624X)
- Jill Caldwell
- Willem de Haan (ORCID: https://orcid.org/0000-0003-3876-1764)
- Hilary A. North
- Charlotte Elisabeth Teunissen (ORCID: https://orcid.org/0000-0002-4061-0837)
- Everard G.B. Vijverberg (ORCID: https://orcid.org/0000-0003-3879-884X)
- Eun-Ah Cho
- Duc M. Duong (ORCID: https://orcid.org/0000-0002-3325-9233)
- Kiran Pandey (ORCID: https://orcid.org/0000-0002-1837-8824)
- Anthony O. Caggiano
- Valentina Di
Institutions
- Emory University (US)
- University of California San Diego (US)
- Cognition Therapeutics (United States) (US)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Alzheimer s & Dementia Translational Research & Clinical Interventions
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/trc2.70119
- Citations
- 1
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- National Institutes of Health
- National Institute on Aging